Zydus Cadila cancer drug Lenalidomide gets USFDA okay

Ahmedabad: Drugmaker, Zydus Cadila, today announced that the company has received tentative approval from the United States Food & Drug Administration (USFDA) to market Lenalidomide Capsules in the strengths of 2.5 mg, 5 mg,10 mg, 15 mg, 20 mg, and 25 mg. (USRLD: Revlimid).

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells.

It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS).

The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 320 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Read also: Zydus Cadila secures USFDA nod for Mesalamine ER Capsules

Zydus Cadila is a global pharmaceutical company headquartered in Ahmedabad, India.

Read also: Zydus Cadila ZyCoV-D likely to get emergency use nod this week: Sources